{"id":"thymopentin","rwe":[{"pmid":"41840011","year":"2026","title":"Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8(+) T cells.","finding":"","journal":"Communications medicine","studyType":"Clinical Study"},{"pmid":"41504129","year":"2026","title":"Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance.","finding":"","journal":"Balkan medical journal","studyType":"Clinical Study"},{"pmid":"41308040","year":"2025","title":"Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study).","finding":"","journal":"Technology in cancer research & treatment","studyType":"Clinical Study"},{"pmid":"41153776","year":"2025","title":"Thymopentin Enhances Antitumor Immunity Through Thymic Rejuvenation and T Cell Functional Reprogramming.","finding":"","journal":"Biomedicines","studyType":"Clinical Study"},{"pmid":"41023915","year":"2025","title":"Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study.","finding":"","journal":"BMC nephrology","studyType":"Clinical Study"}],"tags":[{"label":"thymopentin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L03AX09","category":"atc"},{"label":"Active","category":"status"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"thymopoietin pentapeptide","offLabel":[],"synonyms":["thymopentin","thymopoietin pentapeptide","thymopoietin 32-36"],"timeline":[],"approvals":[],"brandName":"Thymopoietin Pentapeptide","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"thymopentin","explanation":"Think of your immune system like a security team that protects your body from harm. Thymopentin helps the immune system work more efficiently by sending signals to the cells that help fight off infections and diseases. This can help boost the body's defenses and prevent illnesses.","oneSentence":"Thymopentin works by mimicking the action of a natural hormone that helps regulate the immune system.","technicalDetail":"Thymopentin is a synthetic pentapeptide that acts as a thymic hormone analog, modulating the immune response by influencing the activity of T-lymphocytes and other immune cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2645","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=THYMOPENTIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=THYMOPENTIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:53:20.361881","biosimilars":[],"competitors":[{"drugName":"pegademase","drugSlug":"pegademase","fdaApproval":"1990-03-21","relationship":"same-class"},{"drugName":"glatiramer acetate","drugSlug":"glatiramer-acetate","fdaApproval":"1996-12-20","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"histamine","drugSlug":"histamine","fdaApproval":"1939-04-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plerixafor","drugSlug":"plerixafor","fdaApproval":"2008-12-15","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elapegademase","drugSlug":"elapegademase","fdaApproval":"2018-10-05","relationship":"same-class"}],"genericName":"thymopentin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pegademase","brandName":"pegademase","genericName":"pegademase","approvalYear":"1990","relationship":"same-class"},{"drugId":"glatiramer-acetate","brandName":"glatiramer acetate","genericName":"glatiramer acetate","approvalYear":"1996","relationship":"same-class"},{"drugId":"histamine","brandName":"histamine","genericName":"histamine","approvalYear":"1939","relationship":"same-class"},{"drugId":"plerixafor","brandName":"plerixafor","genericName":"plerixafor","approvalYear":"2008","relationship":"same-class"},{"drugId":"elapegademase","brandName":"elapegademase","genericName":"elapegademase","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05978908","phase":"PHASE1","title":"Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults","status":"COMPLETED","sponsor":"Neurodegenerative Disease Research Inc","startDate":"2024-02-20","conditions":["Safety Issues","Tolerance"],"enrollment":24,"completionDate":"2024-06-28"},{"nctId":"NCT06112041","phase":"PHASE2","title":"The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-10-25","conditions":["Carcinoma","Solid Tumor"],"enrollment":29,"completionDate":"2026-10-30"},{"nctId":"NCT00460681","phase":"PHASE3","title":"Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2007-02","conditions":["Hepatocellular Carcinoma"],"enrollment":220,"completionDate":"2012-02"},{"nctId":"NCT00002066","phase":"NA","title":"Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Immunobiology Research Institute","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002109","phase":"PHASE3","title":"Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy","status":"COMPLETED","sponsor":"Immunobiology Research Institute","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002050","phase":"NA","title":"A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients","status":"COMPLETED","sponsor":"Immunobiology Research Institute","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002049","phase":"NA","title":"Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients","status":"COMPLETED","sponsor":"Immunobiology Research Institute","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002289","phase":"NA","title":"The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients","status":"COMPLETED","sponsor":"Immunobiology Research Institute","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002051","phase":"NA","title":"Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Immunobiology Research Institute","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002332","phase":"PHASE2","title":"A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs","status":"COMPLETED","sponsor":"Immunobiology Research Institute","startDate":"","conditions":["HIV Infections"],"enrollment":60,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167482","NDDF":"006776","UNII":"O3Y80ZF13F","CHEBI":"CHEBI:135870","INN_ID":"5146","RXNORM":"40230","UMLSCUI":"C0080225","ChEMBL_ID":"CHEMBL156025","KEGG_DRUG":"D06117","DRUGBANK_ID":"DB11996","PUBCHEM_CID":"451417","MESH_DESCRIPTOR_UI":"D016305"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":444,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L03AX09","allCodes":["L03AX09"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 16","pmid":"41840011","title":"Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8(+) T cells.","journal":"Communications medicine"},{"date":"2026 Jan 8","pmid":"41504129","title":"Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance.","journal":"Balkan medical journal"},{"date":"2025 Jan-Dec","pmid":"41308040","title":"Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study).","journal":"Technology in cancer research & treatment"},{"date":"2025 Oct 13","pmid":"41153776","title":"Thymopentin Enhances Antitumor Immunity Through Thymic Rejuvenation and T Cell Functional Reprogramming.","journal":"Biomedicines"},{"date":"2025 Sep 29","pmid":"41023915","title":"Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study.","journal":"BMC nephrology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"","aiSummary":"Thymopoietin Pentapeptide, also known as Thymopentin, is a small molecule with a modality of a small molecule. It has been studied in clinical trials for conditions such as HIV Infections, Safety Issues, and Tolerance.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}